Project Grant R01DK148720
Award Date 8/5/26
Completion Date 5/31/31
Dollars Obligated $750K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation $561,565 on July 30, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct a Project Grant (R01DK145514) investigating the molecular mechanisms by which testican-2 protects against chronic kidney disease. The award funds research establishing the protective effect of circulating testican-2 in clinically relevant kidney disease...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $251,626 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on c-kit receptor signaling in kidney collecting duct function. The research investigates the role of c-kit receptor signaling in modulating collecting duct epithelial cell composition and function. The project uses c-kit "sash" mice...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $622,959 under Project Grant R01DK146964 on April 15, 2026, to investigate the role of glycerol-3-phosphate acyltransferase 2 (GPAT2) in regulating mineral metabolism dysfunction in chronic kidney disease. The research aims to elucidate a kidney-driven mechanism in which glycerol-3-phosphate released from injured renal tissue stimulates production of fibroblast growth factor 23 (FGF23),...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Icahn School of Medicine at Mount Sinai $816,825 on April 15, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate how injured podocytes communicate with parietal epithelial cells to drive proliferative glomerulopathy, specifically whether podocyte-derived exosomes mediate this cell-to-cell signaling in rapidly progressive glomerulonephritis. The research uses...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $133,875 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project grant funds an evaluation of how estimated glomerular filtration rate (eGFR) decline influences clinical practice patterns of medication withdrawal in heart failure patients. The research addresses a significant...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Vanderbilt University Medical Center $866,265 on May 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate non-canonical ephrin B2 receptor (EPHB2) signaling in acute kidney injury and its progression to chronic kidney disease. The research examines how EPHB2 and transforming growth factor beta signaling pathways contribute to kidney inflammation and...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Medical Center Corporation $152,777 on August 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of uremic toxins as mediators of cardiovascular-kidney-metabolic syndrome and peripheral artery disease in chronic kidney disease patients. The research examines tryptophan-derived uremic toxins, particularly kynurenine and its metabolites, as...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Yale University $623,607 under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) on August 1, 2026. The award funds research examining how impaired double-stranded DNA repair induces podocyte senescence and contributes to chronic kidney disease progression. The project integrates advanced genetic models, including podocyte-specific SETD1A knockout mice that develop focal segmental...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Brigham and Women's Hospital $881,680 on August 21, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop and validate a risk prediction model for proteinuria associated with vascular endothelial growth factor signaling pathway inhibitor (VSPI) therapy. The research aims to identify clinical, biochemical, and genetic risk factors that predict high-grade proteinuria...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded the University of Kansas Medical Center Research Institute, Inc. $334,627 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support basic research on autosomal dominant polycystic kidney disease (ADPKD) cystogenesis. The research targets the sodium-potassium-ATPase (NKA) and its interaction with ouabain, a circulating endogenous compound that the...